Adalimumab therapy for childhood uveitis.
Fourteen children with uveitis (9 JIA associated and 5 idiopathic) were treated with adalimumab for an average of 18.1 months. Inflammation decreased in 21/26 eyes (80.8%), 4 eyes remained stable (15.4%), and 1 worsened (3.8%) (P < .001; 2 tailed paired Wilcoxon rank sum test). No significant adverse events occurred.
Vazquez-Cobian
Liza B
LB
Division of Pediatric Rheumatology, Hospital for Special Surgery, New York, New York 10021, USA.
Flynn
Thomas
T
Lehman
Thomas J A
TJ
D000068879:Adalimumab; D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D011446:Prospective Studies; D014409:Tumor Necrosis Factor-alpha; D014605:Uveitis / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab